Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alliance Pharma ( (GB:APH) ) has issued an announcement.
Alliance Pharma PLC has announced a final increased cash offer from Aegros Bidco Limited, a company indirectly owned by DBAY Affiliates and the ERES IV Fund, for the acquisition of its entire issued and to be issued ordinary share capital. The offer values Alliance at approximately £362 million and represents a significant premium over previous share prices, reflecting confidence in Alliance’s market value. The acquisition is structured as a Court-sanctioned scheme of arrangement and has received a letter of intent from Slater Investments Limited to support the scheme, indicating strong shareholder backing.
More about Alliance Pharma
Alliance Pharma PLC operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is known for its diverse portfolio of healthcare products and its strategic market positioning in the global pharmaceutical sector.
YTD Price Performance: 36.61%
Average Trading Volume: 5,325,910
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £337.9M
See more insights into APH stock on TipRanks’ Stock Analysis page.